JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease
Fousekis FS, Jefremow A, Katsanos KH, Neurath M, Atreya R (2025)
Publication Type: Journal article, Review article
Publication year: 2025
Journal
Book Volume: 18
DOI: 10.1177/17562848251393391
Abstract
Extra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging. Recently, the development of Janus Kinase (JAK) inhibitors has expanded the therapeutic options of luminal IBD, and three JAK inhibitors, tofacitinib, upadacitinib, and filgotinib, have been approved for IBD treatment, while a growing body of evidence suggests that JAK inhibitors may be a promising therapeutic option for the management of EIMs, particularly those affecting the joints and skin. In this comprehensive review, we aim to provide the available evidence concerning the impact of JAK inhibitors on EIMs treatment and analyze their underlying mechanisms of action.
Authors with CRIS profile
Markus Neurath
Lehrstuhl für Innere Medizin I (Medizin 1)
Raja Atreya
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen
Involved external institutions
Greece (GR)How to cite
APA:
Fousekis, F.S., Jefremow, A., Katsanos, K.H., Neurath, M., & Atreya, R. (2025). JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 18. https://doi.org/10.1177/17562848251393391
MLA:
Fousekis, Fotios S., et al. "JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease." Therapeutic Advances in Gastroenterology 18 (2025).
BibTeX: Download